Pasithea Therapeutics (NASDAQ:KTTA) Issues Quarterly Earnings Results

Pasithea Therapeutics (NASDAQ:KTTA) issued its earnings results on Monday. The company reported ($2.41) earnings per share (EPS) for the quarter, Zacks reports.

Pasithea Therapeutics Price Performance

Shares of KTTA stock opened at $1.25 on Wednesday. The stock has a fifty day moving average price of $1.65 and a 200 day moving average price of $2.93. Pasithea Therapeutics has a 1 year low of $0.92 and a 1 year high of $9.25.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.